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Surveillance and isolation for the prevention of methicillin-resistant Staphylococcus aureus (MRSA) has become a
controversial topic, one that causes heated debate and appears to be surrounded by both politics and industrial
conflicts-of-interest. There have been calls from numerous authors for a movement away from rigid mandates and
toward an evidence-based medicine approach. However, much of the evidence can be viewed with an entirely
different interpretation. Two major studies with negative findings have had an adverse impact on recommendations
regarding active detection and isolation (ADI) for MRSA. However the negative findings in these studies can be explained
by shortcomings in study implementation rather than the ineffectiveness of ADI. The use of daily chlorhexidine bathing
has also been proposed as an alternative to ADI in ICU settings. There are shortcomings regarding the evidence in the
literature concerning the effectiveness of daily chlorhexidine bathing. One of the major concerns with universal
daily chlorhexidine bathing is the development of bacterial resistance. The use of surveillance and isolation to
address epidemics and common dangerous pathogens should solely depend upon surveillance and isolation’s
ability to prevent further spread to and infection of other patients through indirect contact. At present, there is
a preponderance of evidence in the literature to support continuing use of surveillance and isolation to prevent
the spread of MRSA.
Keywords: Methicillin-resistant staphylococcus aureus, Surveillance, ADI, Chlorhexidine, Research integrity,
Active detection and isolation, MRSA, CLABSIReview
Introduction
Surveillance and isolation for the prevention of methicillin-
resistant Staphylococcus aureus (MRSA) has become a
controversial topic, one that causes heated debate and
appears to be surrounded by both politics and industrial
conflicts-of-interest. As pointed out by the editorial by
Fätkenheuer, et al. [1], active detection and isolation (ADI)
for MRSA requires significant staff resources. These are
resources that cost-driven institutions may be reluctant to
allocate [2].
There have been calls from numerous authors [3]
along with a recent Lancet editorial by Fätkenheuer,
et al. [1] for a movement away from rigid mandates and* Correspondence: healthwatchusa@gmail.com
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much of the evidence can be viewed with an entirely dif-
ferent interpretation; with many advocating not to set
standards and for a “one size does not fit all’ mentality.
The objective of this article is to offer a counter-opinion
by reassessing the literature as quoted by Fätkenheuer,
et al. [1], and along with other studies put forth an alter-
nate evidence based conclusion.Active detection and isolation
Fätkenheuer, et al. [1] discuss negative findings from two
studies [4,5] that can readily be explained by shortcomings
in study implementation rather than the ineffectiveness of
ADI [3,6,7]. In two additional studies [8,9] involving chlor-
hexidine bathing, the negative results regarding the use of
ADI may have been overstated, in that ADI was not dem-
onstrated to be ineffective. Taken together, whether ADI isral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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upon data interpretation [6,7].
A major study that reported failure of ADI was by
Harbarth, et al. [4], who found that well over half of the
patients who underwent preoperative surveillance and
were known to have MRSA prior to the operation were
not given effective perioperative antibiotics against MRSA.
Additionally, in 31% of the surveillance group, the positive
test results were not available until after surgery. Thus, in
these latter patients, intervention was not possible. Finally,
bias was introduced in this study, along with a question-
able deviation from the standard of care, with the report
that ten patients in the study who developed a MRSA sur-
gical site infection were known carriers prior to surgery
and were not given prophylaxis effective against MRSA.
The next highly cited study that reported the failure of
surveillance to reduce MRSA colonization or infection
was that of Huskins, et al. [5] However, in this study, the
results of admission cultures from the experimental
group were not available for five days [10], and there
was suboptimal staff compliance with contact precaution
protocols. For example, gloves were only used in a me-
dian of 82% of cases, gowns 77%, and hand hygiene 69%
of the time.
In contradistinction, there have been three studies that
have had rigorous controls supporting ADI, those by
Robicsek, et al. [11], Rodriguez-Bano, et al. [12], and
Lee, et al. [13] In addition to isolation, Rodriguez-Bano,
et al. [12] and Lee, et al. [13] also decolonized their pa-
tients. Lee, et al. [13] also observed that, except in clean
surgical wards, ADI and decolonization alone were not
effective, nor was enhanced hand hygiene. These inter-
ventions had to be coupled together before a significant
reduction in MRSA infections was observed.
As discussed in previous reviews [3,6,7], there have
also been many other studies supporting ADI which re-
lied on pre-post designs that have been criticized for not
having concurrent control groups that would detect any
changes over time (secular trends). However, it is pos-
sible that the bias introduced by secular trends can be in
either direction. MRSA infections may increase over
time due to an increased load on a facility of colonized
and infected patients from the community or decrease
due to implementation of seemingly unrelated infection
control protocols in the facility. Nearly all of these stud-
ies have shown a positive effect in MRSA reduction, with
the reduction in many studies reaching statistical signifi-
cance [3,6,7]. The Veterans Health Administration (VA)
has performed large scale studies with reduced rates in
MRSA infections in hospitals [14] and nursing homes
[15] using a bundle approach incorporating ADI. How-
ever, a VA study by Jain, el al [14]. has been criticized for
not controlling for secular trends. Is spite of its limita-
tions, the Jaine, et al. [14], study included almost twomillion admissions with over eight million patient days
and achieved some of the best control rates for MRSA
in the United States.
Chlorhexidine body washes
The use of daily unit-wide chlorhexidine bathing has been
proposed as an alternative to surveillance and isolation
[16]. Two major studies by Huang, et al. (REDUCED
MRSA study) [8], and Derde, et al. [9] found this infec-
tious disease control measure to be efficacious. However,
we disagree with Fätkenheuer, et al. [1] in that neither
study evaluated ADI for MRSA as compared to a no inter-
vention control, and thus, did not show ADI to be “Not
Effective”.
The surveillance and isolation group in the REDUCED
MRSA study did not show a reduction in MRSA clinical
isolates between the ADI baseline and ADI intervention
period. However, the study’s methodology revealed that
patients in both the baseline and intervention period
underwent ADI. Thus, the comparison between the base-
line and intervention arm was to control for secular
trends, not to evaluate ADI.
The REDUCED MRSA study did show a significant re-
duction in MRSA clinical isolates with unit-wide chlor-
hexidine bathing compared to ADI, but the reduction in
MRSA bacteremia did not reach significance. The largest
area of significant reduction was with a reduction in in-
fections in the “Any Pathogen” metric, but the organ-
isms that accounted for the vast majority of the reduced
infections were skin commensal bacteria. However, it
should be noted that although “commensal bacteria”
were not the targeted organisms, they can still cause
dangerous bloodstream infections, especially in im-
munocompromised patients.
Derde, et al. [9] also showed a reduction in MRSA ac-
quisition with improved patient hygiene (enhanced hand
hygiene plus daily chlorhexidine body washing). The
addition of ADI to the improved patient hygiene proto-
col did not provide an additional reduction in MRSA ac-
quisition. We agree with Fätkenheuer, et al. [1] that the
effectiveness attributable to the bundle but disagree
that ADI was shown to be ineffective. There was no
comparison of ADI used alone to a non-intervention
or to a non-chlorhexidine body washing group. Thus,
this study does not preclude the effectiveness of ADI
used alone.
Neither study had a detergent bathing control, which is
important in light of the work of Rotter, et al. [17] who
found that preoperative bathing with chlorhexidine did
not reduce surgical infections compared to bathing with a
detergent. Climo, et al. [18] compared reduction in pri-
mary bloodstream infections with daily bathing using 2%
chlorhexidine gluconate washcloths to daily bathing with
nonantimicrobial washcloths. They did not observe a
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enterococcus (VRE) bloodstream infections in the chlor-
hexidine group compared to the nonantimicrobial wash-
cloth group, possibly related to sample size. They did
observe a decrease in central line associated blood-
stream infections (CLABSIs) and multi-resistant drug
organism acquisitions. The most prominent decrease
in bloodstream infections was for coagulase-negative
staphylococci.
Not all studies have been supportive of the efficacy of
chlorhexidine. In a literature review evaluating preopera-
tive skin antisepsis using chlorhexidine, Maiwald and
Chan [19] could find “no evidence that chlorhexidine
without alcohol was effective” regarding the prevention
of bloodstream or surgical infections. Moreover, many
trials compared chlorhexidine plus alcohol (two antisep-
tics) to povidone-iodine alone (one antiseptic) with sev-
eral trials then attributing the clinical efficiency to
chlorhexidine alone [19]. Although skin antisepsis for
the prep of an operative incisional site is different from
daily bathing, one can argue that a surgical prep is a
more methodical and intense localized application of the
antiseptic and, thus, would be expected to have in-
creased efficacy.
In addition, one major concern with universal daily
chlorhexidine bathing is the production of bacterial re-
sistance. Genes for reduced susceptibility were observed
by Derde, et al. [9] and the incidence showed a slight
non-significant progression between Phase I and Phase
III of their trials (14 of 110 isolates to 16 of 113 isolates).
The Center for Disease Dynamics, Economics & Policy
has shown that it may take decades for resistance to de-
velop and may not be detected in any single trial [20].
Of greater concern are the recent observations by
Suwantarat, et al. [21] who found that patients who were
bathed daily with chlorhexidine were more likely to have
CLABSI caused by organisms that had decreased suscep-
tibility to chlorhexidine, and by Lee, et al. [22] who ob-
served chlorhexidine resistance independently predicted
MRSA decolonization failure.
Industrial conflicts-of-interest
Concerns over industrial influence with the United States’
infectious disease policy was heightened with the contro-
versy surrounding Dr. Charles Denham. Several authors
have suggested [23,24] that Dr. Denham may have used
the study by Darouiche, et al. [25] which evaluated
chlorhexidine-alcohol versus povidone iodine to influence
National Quality Forum (NQF) recommendations re-
garding antiseptics, promoting the use of CareFusion’s
ChloraPrep formulation. According to Policy & Medicine
[24] and Mass Devices [26], the Darouiche, et al. [25]
study was funded by Cardinal Health (later CareFusion)
and one of the authors was a CareFusion employee. Inaddition, Dr. Denham was co-chair of the NQF Safe Prac-
tices Committee. The Centers for Medicare & Medic-
aid Services (CMS) has contracted with NQF to
develop metrics and make recommendations regard-
ing patient safety, to be used in CMS’s value purchas-
ing initiatives.
On Jan. 9, 2014, CareFusion entered into a 40.1 mil-
lion dollar settlement with the United States Department
of Justice to settle allegations that included 11 million
dollars in kickbacks, allegedly given to Dr. Denham by
CareFusion [27]. Dr. Denham has denied any wrong-
doing and there has been no determination of liability.
After the settlement the case is considered closed.
Industrial conflicts-of-interest can also be found in
many studies and are almost impossible to eliminate
[28]. However, all significant conflicts-of-interest need to
be declared. Such was done by one of the authors of the
REDUCED MRSA Study, whose institution conducted
the study, declaring he was on the speaker’s bureau of
“Sage” [8]. The chlorhexidine used in this study was
made by Sage Products [8]. Declaring a conflict-of-
interest does not imply wrongdoing, but if a significant
conflict-of-interest exists, a research study should be
carefully scrutinized before being used as a keystone of
healthcare policy formulation.
Changing of research metrics
Concerns of the REDUCED MRSA study also arose be-
cause of changes in metrics recorded on www.clinicaltrials.
gov more than six months after the trial completion date
[29]. Metrics for urinary cultures and central line associ-
ated blood stream infections were eliminated and the
metric for “Any Pathogens” was added. The latter outcome
was reported as statistically significant. The authors
responded in a letter [30] to a commentary in Anti-
microbial Agents and Chemotherapy (AAC) [3] by
stating all secondary outcomes were declared before
trial completion and data analysis. However, deletions
of metrics after trial initiation should not be allowed,
since it may introduce publication bias and any addi-
tions in metrics should be clearly explained in the
methods section [31]. After publication of the AAC com-
mentary and two years after the study completion date,
the metrics were again changed in www.clinicaltrials.gov
[32] adding back a metric on urinary tract infections and
explaining the data on CLABSI could not be reported due
to problems in standardizing the denominator.
To prevent publication bias all metrics that have been
defined at trial initiation should be reported and new
metrics added should be clearly identified as such in a
trial’s methodology section. Since one may pick and
choose from multiple possible metrics to add post hoc,
the impact of the added metric achieving statistical sig-
nificance is lessened.
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Fätkenheuer, et al. [1] correctly states that hand hygiene
is a crucial intervention in MRSA control. However,
MRSA can also spread by indirect contact and has been
observed to live in the environment on commonly used
plastics for over 51 days [33]. Within 33 hours, 35% of
MRSA colonized patients contaminate their environ-
ment [34] and carriers have been reported to be more
likely to contaminate the environment than infected pa-
tients [35]. Identification of carriers is, thus, imperative.
Although hand hygiene is an indispensable component
in MRSA control, it is unlikely that effective control can
only be achieved with this intervention alone. This pos-
ition is supported by Lee, et al. [13], which found imple-
mentation of enhanced hand hygiene alone was “not
effective” in reducing MRSA.
Lack of strong standards for control of MDROs in the
United States
The recent Ebola epidemic has caused a reevaluation of
the standards in the United States for control of all
MDROs. We have previously reviewed the history of
policy formulation in the United States and concluded
that the lack of firm U.S. standards regarding surveil-
lance and isolation may be driven by a desire to avoid
the enactment of legislative mandates [3]. Even U.S.
standards regarding contact precautions may need to be
strengthened. Stating that “a single patient room is pre-
ferred for patients who require Contact Precautions”
[36] gives facilities an option not to isolate patients.
The type of personnel protective equipment (PPE) is
also not clearly defined or standardized. This is the focus
of a major campaign by the National Nurses United who
advocate for stronger PPE standards that are not “mul-
tiple choice”.
It is obvious that not all contact precautions are the
same. There is variability on both the use of isolation
and the type of protective gear. PPE that covers every
inch of the body and uses N95 respirators will give
greater protection than a surgical mask and gloves. Level
IV Hazmat PPE is also more expensive, more cumber-
some to use and may require specialized training for
donning and doffing. The lack of available effective PPE
and lax standards regarding which PPE to use may have
been an etiological factor in two U.S. healthcare workers
developing a hospital acquired Ebola Infection. As
pointed out by Edmond, et all, further research and de-
velopment is needed for optimizing PPE protection of
our healthcare workers [37].
Conclusion
Based on the analysis of the evidence, we believe policy
formulation regarding MRSA surveillance can be charac-
terized by what the Union of Concerned Scientist refersto as “Downplaying evidence and playing up false uncer-
tainty” [38]. It can be argued that those studies that cast
the greatest doubt on surveillance obtained their nega-
tive findings by not having access to timely test results
or by not taking effective measures once the results were
known. In prominent chlorhexidine bathing studies, a
different analysis of the results appears to mitigate the
positive results. Some might consider these problems to
be below the standard-of-care and the use of these stud-
ies in policy formulation to be inappropriate.
The use of surveillance and isolation to address epi-
demics and common dangerous pathogens should solely
depend upon ADI’s ability to prevent the colonization
and infection of other patients through indirect contact.
One must ask: Why should we treat the MRSA epidemic
any differently from the Ebola epidemic? Being a virus,
Ebola would be expected to have a much shorter lifespan
in the environment than MRSA and, thus, one would
expect not spread as easily through indirect contact. We
have been asked, how can one possibly compare the
two? At the time of this writing we are in the midst of a
very dangerous Ebola epidemic with no end in sight. But
we should not forget MRSA has cost hundreds of thou-
sands of lives and untold disability. To patients that have
been maimed and families that have lost loved ones,
there is little difference between the two.
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